Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
HIV & AIDS
Do you routinely prescribe GLP-1 receptor agonists to people living with HIV (PLH) with obesity?
Nguyen Q, et al. PMID 38501237
Related Questions
How would you manage a patient with well controlled HIV on Biktarvy, who is interested in switching to injectable HAART but also has a history of a prior Hepatitis B Infection?
Is there a role for routine LP in HIV patients with disseminated histoplasmosis even in the absence of CNS signs/symptoms?
In what situations would you use "direct-to-inject" ART, such as Cabenuva, without an oral lead-in?
How do you approach management for patient's with HIV on ART with persistent low level viremia but no new resistance mutations identified?
How do you apply the CDC PrEP guidelines for cisgender women, particularly when faced with underreported risk behaviors or uncertain partner HIV status?
What patient-specific factors would influence your decision to initiate semaglutide therapy in patients with HIV-associated lipohypertrophy?
What are your top takeaways from ID Week 2024?
How do you counsel HIV patients with an undetectable viral load on breastfeeding?
Would you consider using long-acting injectable cabotegravir/rilpivirine for pregnant women with HIV?
What is your approach when cryptococcus serum or CSF antigen titers do not change despite treatment in HIV-positive patients with cryptococcal meningitis or invasive disease, but there is clinical improvement and cultures remain negative?
